Intensity of Mystical Experiences Occasioned by 5-MeO-DMT and Comparison With a Prior Psilocybin Study
Rafael Lancelotta, Austin-Marley Windham-Herman, Kristel Peterson, Joseph P Barsuglia, Alan K. Davis, Robert Palmer, Martin Polanco, Robert M. Grant, Roland R. Griffiths
Frontiers in Psychology December 6, 2018 DOI: 10.3389/fpsyg.2018.02459 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Observational cohort Peer reviewed |
|---|---|
| Sample size | 20 |
| Population | Individuals at a psychospiritual retreat in Mexico |
| Dose | 50 mg of inhaled vaporized toad bufotoxin |
| Measures | Mystical Experience Questionnaire (MEQ30) |
| Topics | Mysticism Psilocybin 5-MeO-DMT DMT Mystical experience |
| Keywords | Hallucinogen Clinical psychology |
| Citations | 80 |
| Key findings | Vaporized 5-MeO-DMT occasioned complete mystical experiences in 75% of participants, with intensity similar to high-dose psilocybin. |
Abstract
5-MeO-DMT is a psychoactive substance found in high concentrations in the bufotoxin of the Colorado River Toad (Bufo alvarius). Emerging evidence suggests that vaporized 5-MeO-DMT may occasion mystical experiences of comparable intensity to those occasioned by more widely studied psychedelics such as psilocybin, but no empirical study has tested this hypothesis. Data was obtained from 20 individuals (M age = 38.9, ± 10.7; male = 55%, Caucasian = 85%) who were administered 5-MeO-DMT as part of a psychospiritual retreat program in Mexico. All participants received 50 mg of inhaled vaporized toad bufotoxin which contains 5-MeO-DMT and completed the Mystical Experience Questionnaire (MEQ30) approximately 4-6 h after their session. Administration of 5-MeO-DMT occasioned strong mystical experiences (MEQ30 Overall M intensity = 4.17, ± 0.64, range 0-5) and the majority (n = 15, 75%) had "a complete mystical experience" (≥60% on all MEQ30 subscales). Compared to a prior laboratory-based psilocybin study, there were no differences in the intensity of mystical effects between 5-MeO-DMT and a high dose (30 mg/70 kg) of psilocybin, but the intensity of mystical effects was significantly higher in the 5-MeO-DMT sample compared to moderate/high dose (20 mg/70 kg) of psilocybin (MEQ30 Total Score: p = 0.02, d = 0.81). Administration of vaporized 5-MeO-DMT reliably occasioned complete mystical experiences in 75% of individuals and was similar in intensity to high dose psilocybin administered in a laboratory setting. The short duration of action may be advantageous for clinical interventions and for studying mystical-type experiences.
Comparable studies
Other observational and cohort studies on 5-MeO-DMT, most cited first.
Citations in the library
Cited by 69
- Predicting Reactions to Psychedelic Drugs: A Systematic Review of States and Traits Related to Acute Drug Effects. ACS Pharmacology & Translational Science March 5, 2021
- A single inhalation of vapor from dried toad secretion containing 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) in a naturalistic setting is related to sustained enhancement of satisfaction with life, mindfulness-related capacities, and a decrement of psychopathological symptoms. Psychopharmacology April 13, 2019
- Development of the Psychological Insight Questionnaire among a sample of people who have consumed psilocybin or LSD Journal of Psychopharmacology January 9, 2021
- Prospective examination of synthetic 5-methoxy-N,N-dimethyltryptamine inhalation: effects on salivary IL-6, cortisol levels, affect, and non-judgment Psychopharmacology December 10, 2019
- The clinical pharmacology and potential therapeutic applications of 5‐methoxy‐N,N‐dimethyltryptamine (5‐MeO‐DMT) Journal of Neurochemistry February 12, 2022
and 64 more in the library
Cites 21
- Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial Journal of Psychopharmacology November 30, 2016
- Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance Psychopharmacology July 7, 2006
- Psilocybin-assisted treatment for alcohol dependence: A proof-of-concept study Journal of Psychopharmacology January 13, 2015
- Psilocybin occasioned mystical-type experiences: immediate and persisting dose-related effects. Psychopharmacology December 1, 2011
- Quality of Acute Psychedelic Experience Predicts Therapeutic Efficacy of Psilocybin for Treatment-Resistant Depression Frontiers in Pharmacology January 17, 2018
and 16 more in the library